Cohance Lifesciences Limited
Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.
What Cohance files
- Investor Meet53
- Others52
- Updates27
- Important20
- Board Meeting7
- PPTs7
#CohanceLifesciences Q1 Update: Revenue Dip, H2 Recovery Expected! **Business Performance:** Cohance Lifesciences saw Q1 revenue drop 23.1% YoY to INR 422.3 Cr, with Adjusted EBITDA at INR 9.2 Cr (2.2% margin). This dip was mainly due to Pharma CDMO shipment delays, softer Agrochemicals, and a significant INR 32.8 Cr loss...
**Business Performance:** Cohance Lifesciences reported FY26 revenue of 2,268 Cr (down 13% YoY) and Q4 revenue of 619 Cr (down 26.3%), impacted by portfolio shifts, inventory, and regulatory issues. CDMO businesses were 52% of FY26 sales. Gross margins improved to 70.8%, with niche technology contributing 18.8% of Q4 revenue, despite...
Cohance Lifesciences reports 9MFY26 revenue of ₹1650 Cr, a 6.7% YoY decline. However, excluding inventory de-stocking, revenue grew 9.3%. Adjusted profit after tax was ₹150 Cr, down 61.4%. Specialty Chemicals grew a strong 31.6%, but Pharma CDMO and API+ saw declines. The company is in a transition phase, focusing on...
Cohance Lifesciences reported an 8% YoY revenue decline in Q2FY26, though adjusting for destocking, growth would have been 14%. Half-year revenue grew modestly by 1.2% to INR 1,104.9 Cr. Adjusted PAT fell to INR 71 Cr in Q2 and INR 130.2 Cr in H1. Pharma CDMO and API+ segments faced...
Here's a summary of the attached file: **1. Financial Highlights:** Q1FY26 revenue grew 13% YoY to INR 549.3 Cr, with gross margin expanding to 73.0%. Adjusted EBITDA reached INR 131.4 Cr (23.9% margin) and Adjusted PAT INR 62.9 Cr (11.4% margin). The company generated INR 232 Cr in free cash...